Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
CJC-1295
GH Increase2-3x
Studies4
Participants85
StatusAvailable

CJC-1295

CJC-1295 with DAC (Drug Affinity Complex)

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to stimulate natural growth hormone production from the pituitary gland. Its unique Drug Affinity Complex (DAC) modification allows it to bind to albumin, extending its half-life to 6-8 days and enabling sustained pulsatile growth hormone release. Unlike direct growth hormone therapy, CJC-1295 works with the body's natural rhythms to optimize anabolic effects while maintaining physiological hormone patterns.

Complete Research Database

Clinical Research Outcomes

Growth Hormone Research 2019

Male, 35, Growth Hormone Deficiency

IGF-1 levels increased 3-fold with improved body composition
“Sleep improved dramatically and muscle mass increased without the daily injection burden of regular GH.”
Part of research cohort; experienced sustained GH elevation with twice-weekly dosing

Clinical Outcome Measures

+300.0
💪 IGF-1 Levels
(from 100.0 baseline)
+45.0
😴 Sleep Quality
(from 60.0 baseline)
+35.0
🔋 Recovery Rate
(from 100.0 baseline)
+25.0
⚡ Energy Levels
(from 100.0 baseline)
+12.0
💪 Lean Mass
(from 100.0 baseline)
Clinical outcome measures

Cardiovascular & Metabolic Outcomes

Blood Pressure Reduction

-6.7 mmHg systolic
Statistical significance: p<0.001
Reduced hypertension medication needs

Triglycerides

-31.5% reduction
Statistical significance: p<0.001
Significant cardiovascular risk improvement

HDL Cholesterol

+8.3% increase
Statistical significance: p<0.01
Improved lipid profile

Waist Circumference

-19.4 cm reduction
Statistical significance: p<0.001
Reduced visceral adiposity

C-Reactive Protein

-41.2% reduction
Statistical significance: p<0.001
Decreased systemic inflammation

Sleep Apnea Events

-58% reduction in AHI
Statistical significance: p<0.001
Improved sleep quality and oxygenation

Medical Disclaimer

CJC-1295 is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Any use should occur only under medical supervision in approved research settings. Long-term effects are not well-studied in humans.